The Russian Direct Investment Fund (RDIF) and Panacea Biotec have started production of Sputnik V in India. Panacea Biotec will now be able to produce 100 million doses in the country every year. RDIF stated that the first batch of vaccines produced by Panacea Biotech will be sent to Sputnik V developer Gamaleya Centre in Russia, for quality control. Its full scale production is expected to begin in summer this year. Established in 1984, Panacea Biotech produces a wide range of drugs and vaccines. The Sputnik V vaccine, registered in 65 countries, uses two different adenovirus vectors in the first and second doses. According to leading medical magazine Lancet, Sputnik V is 91.6% effective against coronavirus infection.
Know more: ANI Twitter